ImmunovantInc Debt Non Current from 2010 to 2024

IMVT Stock  USD 31.43  1.09  3.35%   
Check ImmunovantInc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunovantInc main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 30.1 M or Other Operating Expenses of 251.5 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Price Book Value Ratio of 5.79. ImmunovantInc financial statements analysis is a perfect complement when working with ImmunovantInc Valuation or Volatility modules.
  
This module can also supplement ImmunovantInc's financial leverage analysis and stock options assessment as well as various ImmunovantInc Technical models . Check out the analysis of ImmunovantInc Correlation against competitors.
For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.

About ImmunovantInc Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include ImmunovantInc income statement, its balance sheet, and the statement of cash flows. ImmunovantInc investors use historical funamental indicators, such as ImmunovantInc's Debt Non Current, to determine how well the company is positioned to perform in the future. Although ImmunovantInc investors may use each financial statement separately, they are all related. The changes in ImmunovantInc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ImmunovantInc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ImmunovantInc Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ImmunovantInc. Please read more on our technical analysis and fundamental analysis pages.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether ImmunovantInc is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ImmunovantInc Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Immunovantinc Stock. Highlighted below are key reports to facilitate an investment decision about Immunovantinc Stock:
Check out the analysis of ImmunovantInc Correlation against competitors.
For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for ImmunovantInc Stock analysis

When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.81)
Return On Assets
(0.27)
Return On Equity
(0.45)
The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.